Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Budesonide Nasal Irrigation vs Spray in Allergic Rhinitis
NCT06785662Phase 4Not yet recruiting
- Sponsor
- Siriraj Hospital
- Start
- Feb 2025
- Primary completion
- Jan 2026
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of EPI-EE in allergic rhinitis (AR) (2 arms), sponsored by Siriraj Hospital. Primary endpoint: Total Nasal Symptom Score at 4 weeks. Planned start Feb 2025; status: not yet recruiting.
02
Drugs
EPI-EE
03
Conditions
allergic rhinitis (AR)
Beyond the preview
Go deeper on NCT06785662.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06785662.